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Most investigations into the antimalarial activity of African plants are centered on ﬁnding an indigenous equivalent to artemisinin,
the compound from which current frontline antimalarial drugs are synthesized. As a consequence, the standard practice in
ethnopharmacological research is to use in vitro assays to identify compounds that inhibit parasites at nanomolar concentrations.
This approach fails to take into consideration the high probability of acquisition of resistance to parasiticidal compounds since
parasite populations are placed under direct selection for genetic that confers a survival advantage. Bearing in mind Africa’s long
exposure to malaria and extensive ethnobotanical experimentation with both therapies and diet, it is more likely that compounds
not readily overcome by Plasmodium parasites would have been retained in the pharmacopeia and cuisine. Such compounds are
characterized by acting primarily on the host rather than directly targeting the parasite and thus cannot be adequately explored in
vitro. If Africa’s long history with malaria has in fact produced eﬀective plant therapies, their scientiﬁc elucidation will require a
major emphasis on in vivo investigation.
1.Introduction
In popular African thought, there is a conviction that the
continent’s vast traditional pharmacopeia includes potent
indigenous therapies that can outperform medicines from
industrialized countries [1–3]. This perception appears to be
contradicted by both the historical high burden of malaria
in sub-Saharan Africa and the increasing role played by
foreign medical intervention in Africa’s health crises [4].
With respect to malaria, the current success of artemisinin
combination therapy in reducing transmission rates across
the continent is not matched by results from a comparable
indigenous counterpart [2, 4]. If an African plant therapy
with artemisinin-like epidemiological eﬀects exists, it is
either not currently in widespread use, or its eﬀects are ﬂying
under the radar. The counter argument often heard in Africa
isthatalthoughhighlyeﬀectivecuresdoexist,theyconstitute
hidden knowledge, with the secret formulas held by a few
old men, who will not even on their deathbeds transmit the
information to their own sons [5]. If this is true, then the
traditionofsecrecyservesnopublichealthpurpose,nordoes
it have any future other than extinction.
The narrative of a hidden indigenous cure can be seen as
a response to the success of modern pharmaceutical drugs,
especially in treating severe childhood malaria. To most
observers, the sharp reduction in child mortality rates in
localities where modern treatment is accessible dramatically
emphasizes the performance gap between traditional plant
therapies and packaged tablets obtained in clinics and
pharmacies [2, 4]. Since Africa has a very rich medicinal
planttradition,theapparentfailuretotreatthemillennia-old
scourge of malaria demands an answer or an alibi, which
the stories of secrecy provide. This response to a sense of
failure concedes a frame-of-reference advantage to Western
medicine,whichperceivesanymalariainfectionasunaccept-
able, thus requiring therapies that dramatically change the
status quo [4, 6].
However, when a longer-term view is taken, Africa’s lack
of an indigenous wonder drug has a compelling epidemio-
logical basis. Drugs such as chloroquine were very eﬀective
over a period of decades, but eventually failed. Artemisinin
derivatives are currently very eﬀective, but reports of an
incremental creep in resistance are emerging in many places
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chloroquine or artemisinin that had entered widespread
use, they would in all likelihood have failed as well. Given
Africa’s long exposure to malaria, it is much more logical
to consider the possibility that traditional African therapies
f o c u s e do nt r e a t m e n t sn o te a s i l yo v e r c o m eb yPlasmodium
parasites. Identifying such therapies requires understanding
the diﬀering goals of the conventional pharmaceutical model
compared to the African therapeutic context.
Some herbal medicine advocates argue that whole plant
extractsareinherentlycombinationtherapies,supplyingsev-
eral diﬀerent antimalarial compounds at once, making tradi-
tional plant therapy incapable of driving acquisition of resis-
tance. Historical data to evaluate such a claim are lacking:
for instance, even though the use of Artemisia annua to
treat fever and chills in China was recorded almost 1,700
years ago by Ge Hong [9], we have no way of knowing if
the treatment was either widely known or commonly used
against malaria. There is neither a historical record of fre-
quency and intensity of A. annua use nor a contemporary
study measuring resistance to artemisinin in an area of
current ethnopharmacological use of Artemisia. What we
do know is that potent inhibitory compounds put para-
sites under strong selection pressure that rewards parasite
genetic variations that confer a survival advantage. A fast-
acting compound like artemisinin can put blood stage
parasitesthroughaselectivebottleneckbeforeaccompanying
herbal compounds have an impact, potentially negating
the combination therapy value. Additionally, in a weak or
dilute traditional extract, a compound that inhibits at
nanomolar concentration can still be active, thus selecting
for resistant parasites, while the less potent accompanying
compounds remain below their activity threshold—in eﬀect
functioning as a monotherapy. The point here is that there
may be good epidemiological reasons for why the search for
antimalarial compounds with low nanomolar eﬃcacy has
not yet identiﬁed a potent antiplasmodial plant like A. annua
in the African pharmacopeia.
1.1. Conventional Antimalarial Drug Research. Despite the
aura of secrecy in African ethnomedicine, a considerable cat-
alog of plant species and medicinal applications has emerged
over time, providing an extensive inventory of candidates
for evaluation [10, 11]. Most contemporary research into
Africanantimalarialplantshasbeendirectedtowardsﬁnding
an African equivalent to quinine or artemisinin and is based
almost entirely on in vitro screening [12, 13]. A study
of Kenyan antimalarial plants concluded that the majority
of extracts had low or no activity, with a best IC50 value of
3.65μg/mL [14]. A South African review of 220 antimalarial
plant species identiﬁed just six compounds from in vitro
screenings with IC50 values below 1μg/mL and selectivity
indexes greater than 10 (ten times more inhibition of P.
falciparum than of mammalian cell lines) [15]. The most
potent antiplasmodial compound identiﬁed had an IC50
of 240ng/mL, which is approximately 10-fold weaker than
artemisinin. A similar review of 109 West African plant
species identiﬁed one compound, gedunin, with IC50 values
comparable to artemisinin [16]. Gedunin is a limonoid
tetraterpene from the mahogany family, the members of
whicharewidelyusedfortreatingmalaria[11,17].Although
the in vitro selectivity index of gedunin against mammalian
c e l l sw a sf a v o r a b l e[ 17], extracts from plants in this family
have been found in vivo to act as abortifacients [18, 19].
Toxicity issues are a central concern in IC50 studies geared
towards identifying compounds with high biological activity
at very low doses [15, 20]. However, the large majority
of African plants and extract fractions evaluated have
not killed parasites at submicromolar doses. To date, no
new commercial malaria drug has emerged from in vitro
screening of African plants.
With recent advances in molecular biology and genom-
ics, many malaria drug research programs have adopted a
high tech strategy of identifying a key parasite metabolic or
transcriptional pathway, then developing a suitable assay for
measuring inhibition of the pathway, followed by screening a
vast library of compounds for hits [21–23]. The compound
libraries generally consist of pure compounds that may be
either synthetic or plant derived [24]. Hits are scored on the
basis of inhibition versus concentration: the top performers
or those exhibiting IC50 values below a speciﬁed threshold
are then screened for mammalian cell toxicity [25]. A ﬁnal
short list of compounds is tested in vitro against parasites
to verify activity against live pathogens [26]. Those that do
successfully inhibit parasites are examined in more detail
to verify disruption of the metabolic target. Compounds
emergingfromthisprocessmayﬁnallybetestedinvivousing
a mouse malaria model [27]. The chance of failure during
ﬁrst in vivo use of a drug selected from a blind screening
assay is high: in the absence of a history of mammalian
use, problems at multiple levels are likely to occur. While
technical issues such drug absorption, drug stability, and
metabolism can be tweaked through additional synthetic
manipulation of the identiﬁed compound, they can still
present a signiﬁcant hurdle. Since the molecular structures
of the compounds in the library are known in advance,
computer-aided comparisons of structures can pinpoint
structure-activity relationships [25]. This information in
turn can guide synthesis of analogs that are potentially more
eﬃcacious, more stable, and more readily absorbed in vivo
[23]. Modiﬁed lead compounds that are successful in this
regard still face the considerable challenge of producing
the desired antiparasitic eﬀect in a human host without
also generating unintended consequences. Organisms share
a vast number of the same or similar metabolic and genetic
features, so that a drug acting as desired on a parasite may
yet have unforeseen interactions with related pathways in the
host.
Despite the technical tour-de-force of the high through-
put screening methodology, it is intrinsically a blind process,
in which the ultimate goal of in vivo eﬃcacy is the very last
step to be evaluated. This process is exactly the inverse of
an approach based on African traditional medicine, where
some kind of in vivo eﬃcacy is presumed from common
use, while the mode of action is unknown. It should not
be forgotten that human populations in Africa have been
intensively exposed to malaria over many thousands of
years—thus, a comprehensive high throughput screening of
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with human subjects. The contrast between the empirical,
in vivo traditional approach in endemic malaria areas and
therandom,highthroughput,theoreticalapproach—usually
conducted in laboratories far from the tropics—could hardly
be greater. Despite the fact that in vitro screening of
traditional African antimalarial plants has met with little
success, the screening process continues to be based on the
same assumptions that have produced a series of commercial
drugs with short eﬀective lives. This raises a key question:
If an indigenous plant with rapid parasite knockdown had
been identiﬁed and had entered into widespread use at some
point in Africa’s past, would the therapy have been widely
retained in the traditional pharmacopeia after resistance
emerged? The absence of an African antimalarial compound
with nanomolar antiplasmodial activity should therefore not
be understood as a failure of the pharmacopeia but rather an
indicator that the answer may lie in a diﬀerent direction.
2. Outside-the-Box Epidemiological Contexts
for Drug Development
Rather than supplying the next antiplasmodial wonder drug,
African plants may play a more subtle and more interesting
antimalarial role. Sub-Saharan Africa currently bears the
heaviest burden of malaria worldwide. The presence of long-
term human genetic adaptations to malaria in Africa, such
as hemoglobinopathies and the Duﬀy-negative blood types,
indicates that Plasmodium parasites have exerted genome
changing selection pressure over millennia [28, 29]. There is
evidencethathumangeneticadaptationstomalariainAfrica
may also include selection for tolerance of bitter dietary
compounds with antimalarial activity [30, 31]. Related to
this is the possibility that long-term exposure to malaria
has driven African experimentation with plants and plant
combinations that may alter the bloodstream environment
in which Plasmodium parasites live. These more subtle and
indirect processes may not be detectable in conventional in
vitroscreeningofsingleplantextracts.Suchplant-host-para-
site interactions—discussed in more detail below—represent
promising future research directions with potentially much
higher rewards than merely ﬁnding another single molecule
with nanomolar activity and a short clinical shelf life.
2.1. Acquired Immunity. Endemic malaria areas in sub-
Saharan Africa are characterized by a high level of acquired
“nonsterile” immunity in adults [32]. These adults typically
have blood smears that are positive for Plasmodium, while
their infections are largely asymptomatic. In order to under-
stand how this resistance is acquired, a long-term study in
Senegal compared the malaria epidemiologies of two villages
with diﬀerent transmission rates [33]. When the number of
clinical malaria attacks in the villages was plotted against
age, the trend indicated that there is an initial period of
infant protection conferred via maternal immunity, followed
by a rapid increase in severe malaria among young children,
which subsequently declines later in childhood. The rate of
acquisition of nonsterile immunity was faster in the village
with the higher transmission rate, but was also clearly seen
in the population with the lower transmission site.
While the process of acquisition of malaria immunity
r e ﬂ e c t san a t u r a li m m u n es y s t e mr e s p o n s et oah i g hb u r d e n
of malaria, it also raises the question of whether diet
m i g h ti n ﬂ u e n c ei m m u n ep a r a m e t e r s .T h ee ﬀects of dietary
ﬂavonoids on acquired immunity were modeled using
P. yoelii in mouse trials—the results demonstrated that
oral ingestion of a ﬂavonoid-rich concentrate during initial
infections signiﬁcantly enhanced immune response to rein-
fection after treatment was discontinued [34]. In contrast,
mice receiving pyrimethamine during the initial infection
were vulnerable to severe reinfection when the drug was
withdrawn, showing that drugs that completely eliminate
parasites also stunt the development of immune memory.
In the Senegal study, the introduction of standard-of-care
antimalarial drugs eliminated malaria-related mortality but
substantially increased the incidence of severe malaria [35].
Clearly there is an important long-term beneﬁt to childhood
exposure to parasitic infections, although acquisition of
adult immunity may come at the cost of high infant
mortality. Despite the prevalence of the phenomenon of
acquired immunity in sub-Saharan Africa, the relationship
between traditional plant therapies and immune processes
has not been scientiﬁcally explored in humans in the ﬁeld.
If common dietary compounds such as ﬂavonoids can
inﬂuencetheacquisitionofimmunity,furtherresearchcould
open up a promising new ﬁeld in malaria therapy.
2.2. Diet and Bitter Tasting Compounds. Another possible
role for diet in malaria epidemiology is hinted at in studies
identifying human genetic traits distinctive to Africa. A
potential link between malaria and diet was proposed in
a study comparing the incidence malaria, frequency of
sickle cell anemia and dietary intake of bitter cyanogenic
glucosides present in cassava in Liberia [36]. An inverse
relationship between the cyanide content of human diets
and the frequency of hemoglobin S in four regions of
Liberia suggested that cassava-derived cyanogenic glucosides
might be replacing part of the antimalarial eﬀects of the
hemoglobin S. Sodium cyanate has been found to chemically
modify hemoglobin S, increasing the survival and oxygen
carrying capacity of sickle-cell erythrocytes [37]. Dietary
cyanide levels corresponding to Liberian cassava intake were
shown to signiﬁcantly modify hemoglobin in a swine model,
although it is not clear whether this should increase rather
than decrease sickle cell prevalence [38].
Several reports have noted an elevated frequency of
distinctive alleles conferring a high threshold of bitterness
detection in West African populations in high malaria areas
[30, 31]. This tolerance of bitterness may be reﬂected in the
wide popularity of cola nuts and the bitter tomato (Solanum
incanum L.) and by regional preferences for fruits such
as zegene (Balanites aegyptiaca L.), safou (Dacryodes edulis
(G.Don) Lam), and ronier palm fruits (Borassus aethiopum
Mart.) that are generally rejected by a European palate.
The capacity to taste bitterness derives from specialized
receptors on the tongue that are coded for by TAS2R genes,
w h i c ha r ef o u n di na l lv e r t e b r a t e s[ 39]. TAS2R genes are
believed to be evolutionarily essential, acting as gateway
sensors to bitter—and potentially toxic—compounds [39].4 The Scientiﬁc World Journal
The low-sensitivity K172N allele, representing an earlier
phylogenetic state, is found almost exclusively in tropical
Africa but was subsequently replaced by the N172 mutant,
which confers two-fold greater sensitivity to bitter taste
[30]. This suggests that the evolutionary trade-oﬀ between
avoidance of toxins and protection from malaria changed
after human migration out of Africa [39]. Building on the
earlier proposal of a cassava-malaria link, it was suggested
that dietary cyanogenic glucosides may be the driver behind
selection for reduced detection of bitter taste [30]. How-
ever, cassava is a relatively recent introduction from South
America, while, according to phylogenetic reconstruction
of the global dispersion of TAS2R alleles, high tolerance
of bitter taste in Africa dates back at least 77,000 years
[30, 40]. It is much more likely that other classes of bitter
antimalarial compounds, such as dietary ﬂavonoids with
possible anticytoadherent and immunity-enhancing eﬀects,
would be the drivers for the putative selection for malaria-
related bitterness tolerance.
An additional line of evidence suggesting a strong role
for diet in malaria tolerance comes from nonhuman pri-
mates. It has been observed that while forest monkeys
are commonly infected with simian malarias, Plasmodium
has never been seen in savanna monkeys in the wild, al-
though captive monkeys have been experimentally infected
with P. gonderi [41]. A study of Vervet and Patas mon-
keys in prime mosquito habitat along the Senegal River
in the otherwise arid Ferlo region in northern Senegal
failed to detect Plasmodium, haemosporidia, or microﬁlaria
in blood smears sampled during peak mosquito periods
[41]. Although the authors proposed that the lack of simian
infections might be due to an absence of a mosquito vector
speciﬁc to monkey malaria, this would not account for
the failure to detect haemosporidia or microﬁlaria. There
are several reasons to suspect that the intake of dietary
compounds potentially relevant to malaria and other blood
borne parasites could be substantially diﬀerent between
parasitized rainforest monkeys and unparasitized savanna
monkeys. Savanna vegetation typically has a much higher
contentofmanysecondarymetabolitesthancoolerorrainier
areas [42]. Chemical analyses of plant samples taken along
climate transects across the African savanna north of the
equator show up to 15-fold higher tissue concentrations
for some metabolites in the hottest and driest lowland
savanna areas compared to cooler highlands [43, 44]. It is
well documented that many plant secondary metabolites
are increasingly synthesized under heat and drought stress,
including ﬂavonoids [45, 46]. Since savanna monkey diets
include large quantities of ﬂavonoid-rich leaves and bitter
fruits such as Balanites aegyptiaca, it seems plausible that
these dietary compounds could play a role in reducing
or eliminating simian malaria. Computational analysis of
the TAS2R gene family indicates that primates, includ-
ing monkeys as well as humans, have experienced signif-
icant erosion in capacity to detect bitter taste compared
to mice and a putative common ancestor, suggesting that
an environment-driven evolutionary advantage is involved
[47].
2.3. Plant Combinations. African antimalarial therapies of-
ten feature combinations of several plants. These mixtures
mayincludeanalgesicsandantipyreticsaswellascompounds
that inhibit Plasmodium [11]. Of special interest is the
possibility of chemically or physiologically complementary
eﬀects. Some alkaloids function as monoamine oxidase
inhibitors (MAOis), which reduce the breakdown of active
compounds by enzymes in the digestive tract, which in turn
can result in a much higher uptake into blood plasma [48].
A well-known example of this from Amazonia is ayahuasca,
a shamanic ceremonial and medicinal brew combining an
MAOi donor plant containing harmane alkaloids with other
plants containing visionary alkaloids, especially dimethyl-
tryptamine [49]. While an equivalent traditional system has
not been described in Africa, plants containing the necessary
alkaloids are well represented in traditional pharmacopeias.
Harmane alkaloids exhibit in vitro antiplasmodial activity,
with a modest IC50 of 8μM reported for harmaline alone,
although an additive eﬀectof related compounds in the same
plant may occur [50]. In North Africa, Peganum harmala L.
has analgesic activity and is used to treat fevers and as an all-
purpose medicinal plant [51]. Another harmane-containing
plant, the savanna shrub Guiera senegalensis J.F.Gmel., is
widely used as an antimalarial in the Sahel region [11].
G. senegalensis also contains guieranone, which is reported
to have an in vitro antiplasmodial IC50 of 1.29μM[ 52].
Pureguieranone was,however, foundtobe cytotoxic towards
monocytes and exhibited a low selectivity index, although
the crude alkaloid extract showed low cytotoxicity [52].
Depending on the relative solubilities of harmane alkaloids
andthemorepolarguieranone,traditionalhotwaterextracts
of Guiera may limit the amount of toxic material in the
ﬁnal preparation, which underscores the need for careful
observation of traditional preparations [52]. A traditional
combination of Guiera and Mitragyna inermis extracts
showed strong in vitro synergism against the chloroquine-
resistant W2 P. falciparum strain [52]. A closely related
Southeast Asian tree, M. speciosa, contains over 25 alkaloids,
including 7-hydroxymitragynine, which has an aﬃnity for
opioid receptors and exhibits more potent analgesic activity
than morphine [53]. Although an MAOi eﬀect has yet to
be established in traditional African antimalarial therapies,
some of the speciﬁc plant combinations employed suggest
that this is very likely to be the case.
Traditional African malaria therapies using combina-
tions of plants may also aﬀect active compound metabolism
via interaction with cytochrome P450 (CYP), a large family
of enzymes which account for about 75% of the chemical
modiﬁcationordegradationofdrugsinhumans[54].Asdis-
cussed earlier, African antimalarial plants often contain sig-
niﬁcant concentrations of ﬂavonoids. Quercetin, a ﬂavonoid
found in many plants, has been reported to be an inhibitor
of CYP2C9 and may in other cases function as an inducer
of CYP3A4; although the processes involved are not well
understood, quercetin can potentially alter the serum levels
and the eﬀects of drugs metabolized by these enzymes [55,
56].Naringin,theprincipleﬂavonoidincitrusfruits,inhibits
CYP3A4 and CYP1A2 and can aﬀect drug absorption in the
intestinal tract, potentially increasing or decreasing plasmaThe Scientiﬁc World Journal 5
drug concentrations [57]. Because consumption of normal
dietary quantities of grapefruit or orange juice could aﬀect
circulating drug levels, citrus products may be included in
drug interaction warnings [57]. Since traditional African
combination therapies often involve ﬂavonoid-rich species
and plant parts, CYP interactions may enhance the plasma
levels and activities of components of the preparation. Given
thousands of years of exposure to malaria in Africa, the pos-
sibility that eﬀective empirical combinations have been iden-
tiﬁed by traditional herbalists should be considered. There
may be potential research dividends for closely observing
traditional practices, especially where combination therapies
using ﬂavonoids with strong CYP activities are involved.
2.4. The Problem of Drug Targets. Although plant-based
antimalarialssuchasquinineandartemisininwerealreadyin
ethnopharmaceutical use when ﬁrst encountered by modern
science, the current trend is to generate novel drug targets
[21, 23]. Laboratories located far from the tropics—and
consequently more in touch with technical aspects of the
research and less aware of realities on the ground—have
identiﬁed a multitude of physiologically essential metabolic
pathways that can be targeted to kill parasites [23, 26]. In
most cases, an eﬀective new drug that emerges from this
process and is deployed in the ﬁeld can be expected to have a
dismally short eﬀective life before drug resistance develops,
especially considering the years required for development,
testing, and approval. The use of combination therapies and
the rotation of drugs used in a given locality can slow or
thwartthedevelopmentofresistance;nevertheless,thethreat
ofresistancealwaysremains,withanylapseintheapplication
of the drug administration strategy likely to be punished
w i t har e s u r g e n c eo fs e v e r em a l a r i a[ 35]. The emergence of
drug resistance hinges on the application of direct selection
pressure to the parasite. If a compound kills parasites by
direct contact or exposure, then any genetic or physiological
alterationthatenhancessurvivalwillberetained.Thismeans
that virtually all parasite metabolic targets, no matter how
ingenious, are destined to encounter resistance in the ﬁeld,
should the drug get that far in development.
This is a fundamental problem at both conceptual and
practical levels. However, the problem has an obvious solu-
tion: if long-term, sustainable eﬃcacy is the goal, the therapy
should primarily act upon the host rather than the parasite.
This conclusion is not simply theoretical: it is abundantly
attested to from the ﬁeld, in the numerous human genetic
adaptations to falciparum malaria. There is a growing
body of evidence indicating that all of the malaria-related
hemoglobin variants found in Africa result in a physio-
logically signiﬁcant reduction in parasite cytoadhesion [58,
59]. P. falciparum must bind to endothelial cells lining the
circulatory system to survive in the human host: parasites
that do not cytoadhere will circulate into the spleen, where
the infected red blood cells are detected and destroyed [60].
Thus, the high frequency of hemoglobinopathies in endemic
malaria areas indicates that cytoadhesion is the evolutionary
lever that has worked best against P. falciparum [58, 59].
What sets apart the disruption of cytoadhesion from other
potential host responses to infection is the fact that no direct
selection pressure to parasites is applied. The persistence
of hemoglobinopathies over centuries demonstrates that
malaria parasites have not evolved a viable defense against
anticytoadherence. Following nature’s lead, plant therapies
thattargetcytoadhesionmaystandagoodchanceofavoiding
the drug-resistance cul-de-sac that limits the eﬀective life of
most antimalarial drugs.
2.5. Disruption of Parasite Cytoadhesion by Plant Compounds.
Flavonoids, discussed earlier in their role as likely active
compounds in many traditional African malaria therapies,
have been shown to strongly aﬀect the human endothelial
system at normal dietary plasma concentrations, suggesting
potential for reducing the severity of malaria infections and
facilitating parasite clearance via immune response [34].
Endothelial cells expressing ICAM-1 proteins have been im-
plicated as the principal binding sites for P. falciparum-
infected erythrocytes in cerebral malaria [60]. ICAM-1
receptors in the brain microvasculature can anchor aggre-
gates of infected erythrocytes, platelets, uninfected erythro-
cytes, and immune cells that block blood ﬂow at multiple
sites in the brain, often resulting in convulsions, coma and
fatalities, most commonly in children [60]. ICAM proteins
project out from blood vessel walls into the ﬂow channel,
sometimes shearing oﬀ to generate circulating soluble pro-
tein bodies that can exacerbate the blockage pathology [61].
A study reporting the eﬀects of a cocoa concentrate beverage
in patients at high risk for coronary heart disease found a
mean increase of 76% in upper arm blood ﬂow after six
weeks of daily oral ingestion [61]. Levels of circulating solu-
bleVCAMandlipidsweresigniﬁcantlyreduced.Theseeﬀects
are attributed primarily to epicatechin, a ﬂavonoid found
abundantlyincacaobeansandcolanuts[61,62].Increasesin
plasmaepicatechinalsocorrelatetoincreasesinplasmanitric
oxide levels, which in turn increases vasodilation [61–63].
AcocoaconcentratebeveragetestedonmicewithP. yoelii
infections reduced ﬁrst challenge infections by as much as
50% although the speciﬁc mechanisms involved were not
investigated [34]. Although cytoadhesion occurs in P. yoelii,
all stages of erythrocytic parasites are commonly seen in
peripheral blood, indicating that cytoadhesion is not as crit-
ical in rodent malaria as it is in human infections, with mice
generally dying from hyperparasitemia. In vitro anticytoad-
hesion activity has been documented for epigallocatechin
gallate (EGCG), a ﬂavonoid that is commonly synthesized
in plant leaves and is especially abundant in green tea [64].
EGCG was also found to alter the conformational structure
of merozoite surface protein 1 [65]. Although merozoites do
not cytoadhere, this ﬁnding suggests that it may be worth
investigating the eﬀect of this family of compounds on P.
falciparum erythrocyte membrane proteins. Given the mul-
tiple endothelial and plasma environment altering eﬀects of
ﬂavonoids,asigniﬁcantdisruptionofP.falciparuminfections
is likely.
2.6. Plasma Concentration of Active Compounds. EGCG was
found to competitively bind ICAM-1 in vitro at an IC50 of
5μM[ 64], which is just above the combined peak ﬂavonoid
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drinkers [66]. Since ECGC in vivo would be pulled out of
circulation as it binds to ICAM receptors and plasma lipids,
peak concentration is less critical than the total amount of
drug in circulation, or area under the curve (AUC). It should
be noted that for any drug targeting endothelial receptors,
AUC is a much more relevant measure of competitive bind-
ing potential than peak plasma concentration. An additional
consideration in evaluating ﬂavonoids as anticytoadhesion
drugs is that epicatechin and related compounds commonly
occur as oligomers in plants [67]. Flavonoid oligomers have
been shown to have greater in vitro nonspeciﬁc binding
activity than monomer forms [68]. From this one might
predict that polymerized ﬂavanols will bind endothelial
receptors at lower molar concentrations than monomers,
thusloweringtheplasmalevelsrequiredforsigniﬁcanteﬀect.
Interestingly, the bitter taste of these compounds increases
with the degree of polymerization, which may feed back into
the prevalence of TAS2R alleles conferring low sensitivity to
bitterness in human populations in endemic malaria areas of
Africa.
Polysaccharides constitute another class of polymerized
plant compounds that are potentially anticytoadherent,
althoughaninvestigationofcarrageenansfoundthatbinding
inhibition occurred only at physiologically impractical doses
[69]. Africa has a large number of tree and shrub species that
exude edible polysaccharide-based gums that are commonly
employed in local cuisine and also enter medicinal use [11].
Since endothelial receptors are typically large proteins or
glycoproteins, polysaccharides that are kilodaltons in size
should theoretically be more eﬃcient binders than small
molecules, although they are much more likely to be enzy-
matically degraded as they pass through the digestive tract
before entering blood plasma [69, 70].
Inconventionalthinking,agoodantimalarialplantisone
that possesses an active compound that inhibits Plasmodium
at a few parts per billion, well below the potential plasma
concentration of the orally ingested compound [15, 17,
20]. In contrast, most antimalarial compounds identiﬁed in
African pharmacopeias have relatively weak parasite killing
activity,withinvitroIC50 valuesinpartspermillion[12–16].
Since blood plasma levels of presumed active compounds in
most African antimalarial plants are commonly below the
concentration thresholds for direct antiparasite activity, the
logical conclusion is that the plants are marginally eﬀective
at best, unless other mechanisms are involved. Simply not
enough compound is present to directly inhibit malaria
parasites.
This raises the question of why a plant lacking a com-
pound with nanomolar antiparasitic activity enters into the
local antimalarial pharmacopeia in the ﬁrst place. While the
explanation may be that the compounds are simply treating
fever or inﬂammation, this commentary makes a case for
multiple mechanisms that can potentially change the con-
centration requirements for active compounds. These may
include inﬂuencing immune memory acquisition, inhibiting
or inducing enzymatic processes aﬀecting drug metabolism,
competitive binding of endothelial receptors, increasing
nitric oxide levels, disaggregation of platelets, and vasodi-
lation [34, 61–64]. The most important point with regard
to active compound concentration is that direct parasiticidal
eﬀectsmay not be the goal of traditional African antimalarial
therapy. In fact, from the perspective of maintaining a sus-
tainable, viable indigenous therapy over centuries, direct
elimination of parasites is self defeating.
3. Conclusion
The potential contribution of African plants to mainstream
malaria therapy may take the form of alternative strategies
for treating the disease. Clues from human genetic adapta-
tions to malaria suggest that cytoadhesion may be the key
target. P. falciparum must cytoadhere in order to survive
in a human host. More importantly, while cytoadhesion is
essential to the parasite, interference with cytoadhesion does
not apply direct selection for resistance. It is therefore not
a coincidence that the suite of hemoglobinopathies so far
discovered in Africa reduce the endothelial binding capacity
ofparasites[58,59].Theprevalenceofhostanticytoadhesion
traits in African populations strongly impacted by malaria
represents a long-term evolutionary strategy that can inform
malaria drug development. To date, the potential role of
plants found in African antimalarial pharmacopeias against
cytoadhesion has been largely overlooked.
The historical role of diet as a signiﬁcant component in
the African experience with malaria has also been over-
looked, yet it is strongly hinted at by the prevalence of low
human sensitivity to bitter taste in endemic malaria areas.
Bitter plants in African diets contain several families of
compounds with known antimalarial activity. Despite very
limited research carried out so far, the potential of ﬂavonoids
is especially intriguing since these compounds exhibit a suite
of physiological eﬀects that may counteract cytoadhesion
and enhance immune response to malaria.
One theme running through all of these alternative
mechanismsformalariatherapyisthatinvitroassaysarevery
unlikely to reveal any relevant compound activity. Screening
plants for in vitro nanomolar IC50 values is the standard
approach in plant-based antimalarial research. This ap-
proach unthinkingly assumes that direct control of parasites
is the only viable goal. However, in every known case of an
eﬀectiveplasmodicidaldrugenteringwideuse,parasiteshave
developed resistance [33].
What is an ideal antimalarial drug? An ideal drug is
one that is sustainable, maintaining eﬃcacy over long-term
ﬁeld use. Contrary to the assumption in most antimalarial
compound screening, in vitro tests demonstrating low-dose
antiplasmodial activity may instead serve to ﬂag the com-
pound as a probable driver of resistance against itself. This
argument does not deny the important role in malaria treat-
ment played by drugs that eﬀectively kill parasites at low
doses—these are very much needed for treatment of clinical
malaria. The case is simply being made that long-term,
community-wide use of drugs that apply direct selection
pressuretoparasiteswillalwaysfacetheprospectofemerging
resistance. To get beyond drugs with limited eﬀective life
spans, a much greater emphasis on in vivo testing is required
to capture the interaction between host, parasite, and drug.
While in vivo research can be much more laborious with farThe Scientiﬁc World Journal 7
lower throughput compared to in vitro screening, the host-
centered process may well yield better drugs. In the case of
many antimalarial plants and herbal combination therapies
widely used in African pharmacopeias, in vivo testing may
represent the only means of recognizing and measuring the
eﬃcacy of the traditional therapy.
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